^
    1d
    Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • Monjuvi (tafasitamab-cxix)
    4d
    Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    Calquence (acalabrutinib)
    5d
    Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (clinicaltrials.gov)
    P1, N=100, Recruiting, Newave Pharmaceutical Inc | Trial completion date: Oct 2025 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    LP-118
    8d
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)
    10d
    ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL (clinicaltrials.gov)
    P3, N=306, Recruiting, Newave Pharmaceutical Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    |
    TP53 mutation
    |
    Jaypirca (pirtobrutinib) • rocbrutinib (LP-168)
    11d
    D8220C00036: MAVRiC studies 2L treatment with AV in patients with CLL/SLL who have relapsed after a course of BTKi + BCL2i combination, with and without Obinutuzumab (2024-518858-17-00)
    P1/2, N=25, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    11d
    Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Jennifer Woyach
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • nemtabrutinib (MK-1026)
    18d
    SONIC: Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 30
    Enrollment change
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs) • sonrotoclax (BGB-11417) • Mabtas (rituximab biosimilar)
    19d
    68Ga-pentixafor PET/CT shows better diagnostic performance than 18F-FDG PET/CT in chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and review of literature. (PubMed, Front Oncol)
    Compared with 18F-FDG, 68Ga-pentixafor PET/CT detected more lesions with significantly higher tracer uptake. This case suggests that, for patients with CLL/SLL, 68Ga-pentixafor PET/CT demonstrates significantly superior performance in evaluating the tumor burden and delineating the disease extent compared with 18F-FDG PET/CT.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    19d
    Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma. (PubMed, Pathology)
    Expression of IRTA1 alone, or either IRTA1+ or MNDA+, was less frequent among MZL with plasma cell differentiation than among MZL with classical cell morphology (p=0.063 and 0.071, respectively), albeit not significantly. IRTA1 and MNDA are sensitive and specific markers for the differential diagnosis of MZL, and they may be helpful in distinguishing MZL from histologic mimics.
    Journal
    |
    CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    22d
    Primary Prostatic Alveolar Rhabdomyosarcoma in Adult, a Diagnostic Pitfall: Report of an Extremely Rare Tumor. (PubMed, Int J Surg Pathol)
    The treatment protocol and adjuvant drugs differ significantly from prostatic adenocarcinoma or small cell carcinoma, necessitating an accurate histological diagnosis for appropriate patient management. A molecular work-up can be useful in challenging specimens.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin) • MYOD1 (Myogenic Differentiation 1) • NKX3-1 (NK3 homeobox 1)
    23d
    A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P4, N=150, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Zydelig (idelalisib) • Jaypirca (pirtobrutinib)